 |
|
Conjunctival Allergen ChallengeA Clinical Approach to Studying Allergic Conjunctivitis
Mark B. Abelson, MD;
Wiley A. Chambers, MD;
Lisa M. Smith
Arch Ophthalmol. 1990;108(1):84-88.
Abstract
| |
• To evaluate antiallergic agents, we conducted five allergen challenge studies of increasing refinement. The final study design that evolved included two baseline visits, when skin test-positive subjects were administered a bilateral ocular allergen challenge. At the first visit, the threshold dose of reactivity was determined by increasing allergen doses at 10-minute intervals. At the second baseline visit, 3 days later, the responsive subjects were challenged with the final, highest dose used on visit 1 to assure that the allergic reaction was reproducible and not a cumulative effect of multiple allergen doses. The responsive subjects then returned 3 days later for the drug efficacy evaluation. After a slit-lamp examination, subjects were pretreated with the test drug in one eye and the placebo in the fellow eye in a randomized, double-masked fashion. After 10 minutes, subjects were challenged bilaterally with the allergen dose identified on the previous visits. Postchallenge evaluations of hyperemia, itching, chemosis, eyelid swelling, and tearing were performed at 3, 10, and 20 minutes. Subjects were rechallenged 4 hours after drug administration to assess duration of action. Slit-lamp examinations were again performed at the same intervals as after the initial challenge. A total of 396 subjects were given a baseline allergen challenge; 83.6% responded with a moderate (2+) ocular allergic reaction. Of the 266 given a second baseline challenge, 87.2% responded positively again, suggesting that ocular challenge was highly correlated with skin reactivity and reproducible with a second challenge. No statistically significant difference in redness and itching was found when both eyes were challenged with the same dose of allergen. There was a significant decrease in the allergic reaction of a placebo-pretreated eye compared with its baseline response, and the response to rechallenge was less than the initial one. Of the 950 challenges administered, only two mild systemic reactions occurred, demonstrating the safety of this incremental challenge method. We conclude that this method of allergen challenge is safe, reproducible, and symmetric, but a refractory period may exist when the eye is challenged a third and fourth time in an 8-day period. We now separate the challenge visits by 7 days.
Author Affiliations
From the Department of Immunology, Eye Research Institute, and Department of Ophthalmology, Harvard Medical School, Boston, Mass (Dr Abelson and Ms Smith), and the Division of Anti-Infective Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md (Dr Chambers).
Footnotes
Accepted for publication August 22, 1989.
This article contains the views of the authors and not necessarily those of the Food and Drug Administration.
Reprint requests to 20 Staniford St, Boston, MA 02114 (Dr Abelson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Challenge testing in the diagnosis of occupational allergic conjunctivitis
Wittczak et al.
Occup Med (Lond) 2007;57:532-534.
ABSTRACT
| FULL TEXT
Direct In Vivo Monitoring of Acute Allergic Reactions in Human Conjunctiva
Helinto et al.
J. Immunol. 2004;172:3235-3242.
ABSTRACT
| FULL TEXT
Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus
Mortemousque et al.
Br J Ophthalmol 2004;88:336-340.
ABSTRACT
| FULL TEXT
Efficacy of Ketotifen Fumarate 0.025% Ophthalmic Solution Compared With Placebo in the Conjunctival Allergen Challenge Model
Abelson et al.
Arch Ophthalmol 2003;121:626-630.
ABSTRACT
| FULL TEXT
The Relative Contribution of Mast Cell Subsets to Conjunctival TH2-like Cytokines
Anderson et al.
IOVS 2001;42:995-1001.
ABSTRACT
| FULL TEXT
Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model
Leonardi et al.
Br J Ophthalmol 2000;84:1228-1232.
ABSTRACT
| FULL TEXT
Allergic eye disease mechanisms
McGILL et al.
Br J Ophthalmol 1998;82:1203-1214.
FULL TEXT
Effects of Vasocon-A in the Allergen Challenge Model of Acute Allergic Conjunctivitis
Abelson et al.
Arch Ophthalmol 1990;108:520-524.
ABSTRACT
|
